| 1 | Hyperarousal features in the sleep architecture of individuals with and without insomnia | 3.8 | 14 | Citations (PDF) |
| 2 | Narcolepsy and rapid eye movement sleep | 3.8 | 9 | Citations (PDF) |
| 3 | Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by CPAP: Randomised phase 3 study | 3.8 | 8 | Citations (PDF) |
| 4 | Daytime sleepiness and BMI exhibit gender and age differences in patients with central disorders of hypersomnolence | 3.8 | 4 | Citations (PDF) |
| 5 | Absence of dysregulation in amplitude and phase of circadian rhythm of core body temperature in idiopathic hypersomnia: a case–control study | 0.9 | 6 | Citations (PDF) |
| 6 | Talking to sleepwalkers? Response to communication efforts in disorders of arousals | 0.9 | 3 | Citations (PDF) |
| 7 | Interim analysis of a post-authorization safety study of pitolisant in treating narcolepsy: A real-world European study | 1.7 | 3 | Citations (PDF) |
| 8 | L’hypothèse circadienne dans l’hypersomnie idiopathique : une étude de la température interne | 0.1 | 0 | Citations (PDF) |
| 9 | Determinants of substance use patterns in patients with narcolepsy type 1: A multi-center comparative cross-sectional study | 1.7 | 0 | Citations (PDF) |
| 10 | Use of Portable 24-Hour Polysomnography as Alternative Diagnostic Tool for Narcolepsy Type 1 in Adults and Children | 1.0 | 3 | Citations (PDF) |
| 11 | Clinical and objective correlates of disrupted nighttime sleep in pediatric narcolepsy type 1 | 1.7 | 2 | Citations (PDF) |
| 12 | Association of Sleep Disruption With Daytime Sleepiness in Patients With Restless Legs Syndrome | 1.0 | 4 | Citations (PDF) |
| 13 | Sex effect on disease characteristics in patients with narcolepsy type 1 | 0.9 | 1 | Citations (PDF) |
| 14 | Effect of daridorexant on nighttime wakefulness and next-morning sleepiness: assessing the transition from night to day in insomnia disorder | 1.7 | 0 | Citations (PDF) |
| 15 | LRRK2 rare-variant per-domain genetic burden in Parkinson’s Disease: association confined to the kinase domain | 7.0 | 2 | Citations (PDF) |
| 16 | Efficacy and Safety of Sodium Oxybate in Adults With Idiopathic Hypersomnia | 1.0 | 5 | Citations (PDF) |
| 17 | Unraveling the pathophysiology of narcolepsy type 1 through hypothesis-driven and hypothesis-generating approaches | 6.7 | 3 | Citations (PDF) |
| 18 | Oveporexton, an Oral Orexin Receptor 2–Selective Agonist, in Narcolepsy Type 1 | 34.6 | 23 | Citations (PDF) |
| 19 | Hypothalamic volume, sleep, and APOE genotype in cognitively healthy adults | 0.5 | 4 | Citations (PDF) |
| 20 | Weight changes during treatment with low-sodium oxybate in two phase 3 clinical studies in participants with narcolepsy or idiopathic hypersomnia | 1.7 | 1 | Citations (PDF) |
| 21 | Shedding light on microsleep episodes for comprehensive sleepiness assessment: a narrative review | 8.7 | 2 | Citations (PDF) |
| 22 | Systematic Assessment of Dysexecutive Syndrome, Hypersomnolence and Dysautonomia in Kleine‐Levin Syndrome | 3.5 | 0 | Citations (PDF) |
| 23 | Sleep Disruption and Atrial Fibrillation: Evidence, Mechanisms and Clinical Implications | 13.2 | 3 | Citations (PDF) |
| 24 | Restless Legs Syndrome, Periodic Leg Movements, Hypertension and Cardiovascular Diseases | 13.2 | 3 | Citations (PDF) |
| 25 | Long COVID as a risk factor for hypersomnolence and fatigue: insights from the 2nd International Covid Sleep Study Collaboration (ICOSS-2) | 1.7 | 0 | Citations (PDF) |
| 26 | Functional recovery after ischemic stroke: Impact of different sleep health parameters | 3.8 | 12 | Citations (PDF) |
| 27 | The role of cardiovascular health and vascular events in the relationship between excessive daytime sleepiness and dementia risk | 3.8 | 7 | Citations (PDF) |
| 28 | Somnambulism | 4.3 | 3 | Citations (PDF) |
| 29 | Long-Term Efficacy and Safety of Pitolisant for Residual Sleepiness Due to OSAChest, 2024, 165, 692-703 | 1.0 | 18 | Citations (PDF) |
| 30 | Spoken Language Alterations can Predict Phenoconversion in Isolated Rapid Eye Movement Sleep Behavior Disorder: A Multicenter Study | 6.6 | 21 | Citations (PDF) |
| 31 | Challenges in diagnosing NREM parasomnias: Implications for future diagnostic classifications | 8.7 | 14 | Citations (PDF) |
| 32 | Effects of oxybate dose and regimen on disrupted nighttime sleep and sleep architecture | 1.7 | 8 | Citations (PDF) |
| 33 | Narcolepsy Severity Scale-2 and Idiopathic Hypersomnia Severity Scale to better quantify symptoms severity and consequences in Narcolepsy type 2 | 0.9 | 20 | Citations (PDF) |
| 34 | Association between idiopathic hypersomnia and a genetic variant in the PER3 gene | 3.8 | 6 | Citations (PDF) |
| 35 | Trajectories of self-reported daytime sleepiness post-ischemic stroke and transient ischemic attack: A propensity score matching study versus non-stroke patients | 3.8 | 3 | Citations (PDF) |
| 36 | Estimation bias and agreement limits between two common self-report methods of habitual sleep duration in epidemiological surveys | 3.4 | 9 | Citations (PDF) |
| 37 | Comparison of demographics and baseline narcolepsy symptoms between participants with NT1 and NT2 from the Phase 3 REST-ON clinical trial | 1.7 | 0 | Citations (PDF) |
| 38 | Magnitude of improvement in excessive daytime sleepiness with the once-at-bedtime oxybate for narcolepsy | 1.7 | 0 | Citations (PDF) |
| 39 | Application of AASM clinical significance thresholds to once-nightly sodium oxybate for improvement in narcolepsy symptoms | 1.7 | 0 | Citations (PDF) |
| 40 | Composite response with once-nightly sodium oxybate: symptom improvement in participants with narcolepsy type 1 in REST-ON | 1.7 | 0 | Citations (PDF) |
| 41 | Consistent efficacy of once-nightly sodium oxybate regardless of patient demographic and baseline disease characteristics | 1.7 | 0 | Citations (PDF) |
| 42 | Characterization of patients who had ≥5% weight loss with once-nightly sodium oxybate: post hoc analysis from REST-ON | 1.7 | 0 | Citations (PDF) |
| 43 | Nightmare frequency is a risk factor for suicidal ideation during the COVID‐19 pandemic | 3.8 | 11 | Citations (PDF) |
| 44 | Long sleep time and excessive need for sleep: State of the art and perspectives | 2.2 | 10 | Citations (PDF) |
| 45 | Absence of specific autoantibodies in patients with narcolepsy type 1 as indicated by an unbiased random peptide-displayed phage screening | 2.3 | 3 | Citations (PDF) |
| 46 | Guidelines for the assessment and management of residual sleepiness in obstructive apnea-hypopnea syndrome | 0.4 | 5 | Citations (PDF) |
| 47 | Effect of daridorexant on sleep architecture in patients with chronic insomnia disorder: a pooled post hoc analysis of two randomized phase 3 clinical studies | 0.9 | 10 | Citations (PDF) |
| 48 | Restless legs symptoms increased during COVID-19 pandemic. International ICOSS-survey | 1.7 | 6 | Citations (PDF) |
| 49 | Single cell transcriptomics of cerebrospinal fluid cells from patients with recent-onset narcolepsy | 6.6 | 7 | Citations (PDF) |
| 50 | Identifying time‐resolved features of nocturnal sleep characteristics of narcolepsy using machine learning | 3.8 | 11 | Citations (PDF) |
| 51 | Microglia Density and Its Association With Disease Duration, Severity, and Orexin Levels in Patients With Narcolepsy Type 1 | 1.0 | 10 | Citations (PDF) |
| 52 | Genome-wide meta-analyses of restless legs syndrome yield insights into genetic architecture, disease biology and risk prediction | 25.2 | 40 | Citations (PDF) |
| 53 | PET Study of Microglial Activation in Kleine-Levin Syndrome | 6.7 | 4 | Citations (PDF) |
| 54 | REM sleep in narcolepsy | 8.7 | 13 | Citations (PDF) |
| 55 | Weight Loss With Once-nightly Sodium Oxybate for the Treatment of Narcolepsy: Analysis From the Phase III Randomized study Evaluating the efficacy and SafeTy of a ONce nightly formulation of sodium oxybate (REST-ON) Trial | 2.7 | 3 | Citations (PDF) |
| 56 | Efficacy of once-nightly sodium oxybate (FT218) on daytime symptoms in individuals with narcolepsy with or without concomitant alerting agent use: A post hoc analysis from the phase 3 REST-ON trial | 1.7 | 3 | Citations (PDF) |
| 57 | Comparative efficacy, safety and benefit/risk of alerting agents for excessive daytime sleepiness in patients with obstructive sleep apnoea: a network meta-analysis | 8.2 | 15 | Citations (PDF) |
| 58 | Are rare heterozygous SYNJ1 variants associated with Parkinson’s disease? | 7.0 | 1 | Citations (PDF) |
| 59 | The Parkinson’s disease risk gene cathepsin B promotes fibrillar alpha-synuclein clearance, lysosomal function and glucocerebrosidase activity in dopaminergic neurons | 14.1 | 24 | Citations (PDF) |
| 60 | Dream‐enactment behaviours during the COVID‐19 pandemic: an international COVID‐19 sleep study | 3.8 | 20 | Citations (PDF) |
| 61 | Home nocturnal infrared video to record non‐rapid eye movement sleep parasomnias | 3.8 | 18 | Citations (PDF) |
| 62 | Rapid eye movement sleep duration during the multiple sleep latency test to diagnose hypocretin-deficient narcolepsy | 0.9 | 15 | Citations (PDF) |
| 63 | GALC variants affect galactosylceramidase enzymatic activity and risk of Parkinson’s diseaseBrain, 2023, 146, 1859-1872 | 8.4 | 34 | Citations (PDF) |
| 64 | The role of sleep and dreams in long‐COVID | 3.8 | 27 | Citations (PDF) |
| 65 | Sleepiness in adults: An umbrella review of a complex construct | 8.7 | 29 | Citations (PDF) |
| 66 | Cognitive strategies to improve symptoms of restless legs syndrome | 3.8 | 6 | Citations (PDF) |
| 67 | Shift workers are at increased risk of severe COVID-19 compared with day workers: Results from the international COVID sleep study (ICOSS) of 7141 workers | 1.9 | 8 | Citations (PDF) |
| 68 | Update on the treatment of idiopathic hypersomnia: Progress, challenges, and expert opinion | 8.7 | 41 | Citations (PDF) |
| 69 | Persistent short nighttime sleep duration is associated with a greater post-COVID risk in fully mRNA-vaccinated individuals | 5.2 | 18 | Citations (PDF) |
| 70 | Brain‐derived neurotrophic factor (BDNF) variants and promoter I methylation are associated with prolonged nocturnal awakenings in older adults | 3.8 | 2 | Citations (PDF) |
| 71 | Progression of clinical markers in prodromal Parkinson’s disease and dementia with Lewy bodies: a multicentre studyBrain, 2023, 146, 3258-3272 | 8.4 | 101 | Citations (PDF) |
| 72 | NPC1 variants are not associated with Parkinson’s disease, REM-sleep behavior disorder or dementia with Lewy bodies in European cohorts | 3.4 | 7 | Citations (PDF) |
| 73 | Safety and efficacy of pitolisant in children aged 6 years or older with narcolepsy with or without cataplexy: a double-blind, randomised, placebo-controlled trial | 17.9 | 27 | Citations (PDF) |
| 74 | Impact of a telerehabilitation programme combined with continuous positive airway pressure on symptoms and cardiometabolic risk factors in obstructive sleep apnea patients | 2.0 | 4 | Citations (PDF) |
| 75 | Cerebrospinal fluid proteomics in recent-onset Narcolepsy type 1 reveals activation of the complement system | 4.9 | 7 | Citations (PDF) |
| 76 | Autonomic Dysfunction in Hypersomnia | 1.7 | 0 | Citations (PDF) |
| 77 | Association between hypersomnolence and the COVID-19 pandemic: The International COVID-19 Sleep Study (ICOSS) | 1.7 | 13 | Citations (PDF) |
| 78 | Efficacy of once-nightly sodium oxybate (FT218) in narcolepsy type 1 and type 2: post hoc analysis from the Phase 3 REST-ON Trial | 0.9 | 12 | Citations (PDF) |
| 79 | Association of Rare Variants in ARSA with Parkinson's Disease | 4.6 | 9 | Citations (PDF) |
| 80 | Narcolepsy risk loci outline role of T cell autoimmunity and infectious triggers in narcolepsy | 13.7 | 49 | Citations (PDF) |
| 81 | The immunopathogenesis of narcolepsy type 1 | 53.8 | 59 | Citations (PDF) |
| 82 | HLA in isolated REM sleep behavior disorder and Lewy body dementia | 3.8 | 7 | Citations (PDF) |
| 83 | Number, Duration, and Distribution of Wake Bouts in Patients with Insomnia Disorder: Effect of Daridorexant and Zolpidem | 6.3 | 19 | Citations (PDF) |
| 84 | Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1 | 34.6 | 73 | Citations (PDF) |
| 85 | Cardiovascular burden of narcolepsy: what have we learned and what do we still need to know? | 0.9 | 13 | Citations (PDF) |
| 86 | Recommandations pour le bilan et la prise en charge de la somnolence résiduelle dans le syndrome d’apnées-hypopnées obstructives du sommeil | 0.1 | 5 | Citations (PDF) |
| 87 | The association of insomnia with long COVID: An international collaborative study (ICOSS-II) | 1.7 | 20 | Citations (PDF) |
| 88 | The indirect relationship between sleep and cognition in the PREVENT cohort: identifying targets for intervention | 0.8 | 1 | Citations (PDF) |
| 89 | Associations between changes in habitual sleep duration and lower self-rated health among COVID-19 survivors: findings from a survey across 16 countries/regions | 3.1 | 3 | Citations (PDF) |
| 90 | The transcriptomics profiling of blood CD4 and CD8 T-cells in narcolepsy type I | 4.9 | 7 | Citations (PDF) |
| 91 | Symptom network analysis of the sleep disorders diagnostic criteria based on the clinical text of the ICSD‐3 | 3.8 | 14 | Citations (PDF) |
| 92 | Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy | 0.9 | 47 | Citations (PDF) |
| 93 | Evening-types show highest increase of sleep and mental health problems during the COVID-19 pandemic—multinational study on 19 267 adults | 0.9 | 64 | Citations (PDF) |
| 94 | Disrupted nighttime sleep and sleep instability in narcolepsy | 2.8 | 79 | Citations (PDF) |
| 95 | Sleep inertia measurement with the psychomotor vigilance task in idiopathic hypersomnia | 0.9 | 41 | Citations (PDF) |
| 96 | Histamine in murine narcolepsy: What do genetic and immune models tell us? | 5.0 | 11 | Citations (PDF) |
| 97 | Rare PSAP Variants and Possible Interaction with GBA in REM Sleep Behavior Disorder | 3.3 | 9 | Citations (PDF) |
| 98 | Influenza vaccination induces autoimmunity against orexinergic neurons in a mouse model for narcolepsyBrain, 2022, 145, 2018-2030 | 8.4 | 26 | Citations (PDF) |
| 99 | Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study | 17.9 | 57 | Citations (PDF) |
| 100 | Risk Factors for Phenoconversion in Rapid Eye Movement Sleep Behavior Disorder | 6.6 | 56 | Citations (PDF) |
| 101 | Complaints of daytime sleepiness, insomnia, hypnotic use, and risk of dementia: a prospective cohort study in the elderly | 6.6 | 36 | Citations (PDF) |
| 102 | Depressive Symptoms and Suicidal Thoughts in Restless Legs Syndrome | 4.6 | 28 | Citations (PDF) |
| 103 | Disturbances in sleep, circadian rhythms and daytime functioning in relation to coronavirus infection and Long‐COVID – A multinational ICOSS study | 3.8 | 32 | Citations (PDF) |
| 104 | Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution: A Lower-Sodium Alternative for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy | 4.1 | 14 | Citations (PDF) |
| 105 | Linking clinical complaints and objective measures of disrupted nighttime sleep in narcolepsy type 1 | 0.9 | 26 | Citations (PDF) |
| 106 | Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON Trial | 6.3 | 27 | Citations (PDF) |
| 107 | Narcolepsy with intermediate cerebrospinal level of hypocretin-1 | 0.9 | 26 | Citations (PDF) |
| 108 | Does the adenosine deaminase (ADA) gene confer risk of sleepwalking? | 3.8 | 7 | Citations (PDF) |
| 109 | 0389 Efficacy of Lower-Sodium Oxybate in the Treatment of Idiopathic Hypersomnia: Evaluation of Response Based on the Epworth Sleepiness Scale ScoreSleep, 2022, 45, A174-A175 | 0.9 | 0 | Citations (PDF) |
| 110 | Narcolepsy | 3.8 | 57 | Citations (PDF) |
| 111 | Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications | 6.3 | 11 | Citations (PDF) |
| 112 | 0387 Weight Changes During Treatment With Lower-Sodium Oxybate in a Phase 3 Clinical Study in Patients With Idiopathic HypersomniaSleep, 2022, 45, A173-A174 | 0.9 | 2 | Citations (PDF) |
| 113 | 0393 Weight Changes During Treatment With Lower-Sodium Oxybate in a Phase 3 Clinical Study in Patients With NarcolepsySleep, 2022, 45, A176-A176 | 0.9 | 3 | Citations (PDF) |
| 114 | 0390 Efficacy of Lower-Sodium Oxybate in the Treatment of Idiopathic Hypersomnia: Evaluation of Response Based on the Idiopathic Hypersomnia Severity Scale ScoreSleep, 2022, 45, A175-A175 | 0.9 | 0 | Citations (PDF) |
| 115 | The orexin story, sleep and sleep disturbances | 3.8 | 62 | Citations (PDF) |
| 116 | Proteomic biomarkers of Kleine–Levin syndrome | 0.9 | 8 | Citations (PDF) |
| 117 | Orexin 2 receptor–selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients | 7.5 | 77 | Citations (PDF) |
| 118 | Changes in Sleep Pattern During the COVID-19 Lockdown in Patients With Narcolepsy, Idiopathic Hypersomnia, and Restless Legs Syndrome | 1.0 | 13 | Citations (PDF) |
| 119 | Understanding and approaching excessive daytime sleepiness | 62.3 | 164 | Citations (PDF) |
| 120 | Impact of Obstructive Sleep Apnea Syndrome on Ventricular Remodeling after Acute Myocardial Infarction: A Proof-of-Concept Study | 2.5 | 1 | Citations (PDF) |
| 121 | Early onset of sleep/wake disturbances in a progressive macaque model of Parkinson’s disease | 3.4 | 16 | Citations (PDF) |
| 122 | Clinical considerations for the diagnosis of idiopathic hypersomnia | 8.7 | 54 | Citations (PDF) |
| 123 | Genome-wide association study of REM sleep behavior disorder identifies polygenic risk and brain expression effects | 13.7 | 77 | Citations (PDF) |
| 124 | Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder | 6.3 | 70 | Citations (PDF) |
| 125 | Maintenance of wakefulness test: how does it predict accident risk in patients with sleep disorders? | 1.7 | 37 | Citations (PDF) |
| 126 | ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice | 6.8 | 62 | Citations (PDF) |
| 127 | Analysis of Heterozygous
PRKN
Variants and Copy‐Number Variations in Parkinson's Disease | 4.6 | 50 | Citations (PDF) |
| 128 | Socioeconomic impact of restless legs syndrome and inadequate restless legs syndrome management across European settings | 3.5 | 41 | Citations (PDF) |
| 129 | Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy | 0.9 | 63 | Citations (PDF) |
| 130 | Characteristics associated with hypersomnia and excessive daytime sleepiness identified by extended polysomnography recording | 0.9 | 30 | Citations (PDF) |
| 131 | Targeted sequencing of Parkinson’s disease loci genes highlights
SYT11, FGF20
and other associationsBrain, 2021, 144, 462-472 | 8.4 | 52 | Citations (PDF) |
| 132 | Pitolisant for Residual Excessive Daytime Sleepiness in OSA Patients Adhering to CPAPChest, 2021, 159, 1598-1609 | 1.0 | 71 | Citations (PDF) |
| 133 | Sleep-related head jerks: toward a new movement disorder | 0.9 | 13 | Citations (PDF) |
| 134 | New 2013 incidence peak in childhood narcolepsy: more than vaccination? | 0.9 | 20 | Citations (PDF) |
| 135 | Cerebrospinal fluid monoamine levels in central disorders of hypersomnolence | 0.9 | 26 | Citations (PDF) |
| 136 | Kleine-Levin syndrome is associated with birth difficulties and genetic variants in the
TRANK1
gene loci | 7.5 | 42 | Citations (PDF) |
| 137 | Systematic assessment of autonomic symptoms in restless legs syndrome | 1.7 | 12 | Citations (PDF) |
| 138 | Association study of DNAJC13, UCHL1, HTRA2, GIGYF2, and EIF4G1 with Parkinson's disease | 3.4 | 39 | Citations (PDF) |
| 139 | The association between high risk of sleep apnea, comorbidities, and risk of COVID-19: a population-based international harmonized study | 1.5 | 44 | Citations (PDF) |
| 140 | 344 Daridorexant Improves Total Sleep Time (TST) in Insomnia Patients Without Altering the Proportion of Sleep StagesSleep, 2021, 44, A137-A138 | 0.9 | 1 | Citations (PDF) |
| 141 | Speech Biomarkers in Rapid Eye Movement Sleep Behavior Disorder and Parkinson Disease | 6.6 | 119 | Citations (PDF) |
| 142 | 485 Efficacy and Safety of Once- and Twice-Nightly Dosing of Lower-Sodium Oxybate in Adults With Idiopathic HypersomniaSleep, 2021, 44, A191-A192 | 0.9 | 1 | Citations (PDF) |
| 143 | 487 Effect of Lower-Sodium Oxybate on Sleep Inertia in Idiopathic Hypersomnia in a Double-Blind, Randomized Withdrawal StudySleep, 2021, 44, A192-A192 | 0.9 | 0 | Citations (PDF) |
| 144 | 489 Pivotal Phase 3 Study of FT218, a Once-Nightly Sodium Oxybate Formulation, in Patients With Narcolepsy: REST-ON Primary ResultsSleep, 2021, 44, A193-A193 | 0.9 | 2 | Citations (PDF) |
| 145 | 488 REST-ON: Efficacy of FT218 for Daytime Sleepiness, Sleep Quality, Hallucinations, and Sleep Paralysis in Patients With NarcolepsySleep, 2021, 44, A192-A193 | 0.9 | 0 | Citations (PDF) |
| 146 | 500 Correlation of the Idiopathic Hypersomnia Severity Scale With Other Measures of Sleep Parameters in a Phase 3 TrialSleep, 2021, 44, A197-A197 | 0.9 | 1 | Citations (PDF) |
| 147 | Measurement of Narcolepsy Symptoms in School-Aged Children and Adolescents | 1.0 | 29 | Citations (PDF) |
| 148 | 2018 worldwide survey of health-care providers caring for patients with narcolepsy | 1.7 | 7 | Citations (PDF) |
| 149 | Le pneumologue face à la somnolence diurne | 0.0 | 1 | Citations (PDF) |
| 150 | European guideline and expert statements on the management of narcolepsy in adults and children | 3.5 | 121 | Citations (PDF) |
| 151 | Self-perceived sleep during the Maintenance of Wakefulness Test: how does it predict accidental risk in patients with sleep disorders? | 0.9 | 9 | Citations (PDF) |
| 152 | European guideline and expert statements on the management of narcolepsy in adults and children | 3.8 | 93 | Citations (PDF) |
| 153 | A systematic analysis of ICSD-3 diagnostic criteria and proposal for further structured iteration | 8.7 | 58 | Citations (PDF) |
| 154 | Cardiovascular disorders in narcolepsy: Review of associations and determinants | 8.7 | 71 | Citations (PDF) |
| 155 | Insomnia, anxiety, and depression during the COVID-19 pandemic: an international collaborative study | 1.7 | 273 | Citations (PDF) |
| 156 | Novel Associations of
BST1
and
LAMP3
With REM Sleep Behavior Disorder | 1.0 | 17 | Citations (PDF) |
| 157 | Video-Polysomnographic Assessment for the Diagnosis of Disorders of Arousal in Children | 1.0 | 16 | Citations (PDF) |
| 158 | Restless legs syndrome | 47.2 | 216 | Citations (PDF) |
| 159 | Prognostic Impact of Sleep Patterns and Related-Drugs in Patients with Heart Failure | 2.5 | 3 | Citations (PDF) |
| 160 | Time to Onset of Response to Pitolisant for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients With Narcolepsy: An Analysis of Randomized, Placebo-Controlled Trials | 6.3 | 5 | Citations (PDF) |
| 161 | Sleep and daytime problems during the COVID-19 pandemic and effects of coronavirus infection, confinement and financial suffering: a multinational survey using a harmonised questionnaire | 1.9 | 56 | Citations (PDF) |
| 162 | Association of Inattention, Hyperactivity, and Hypersomnolence in Two Clinic-Based Adult Cohorts | 2.8 | 31 | Citations (PDF) |
| 163 | Natural history of excessive daytime sleepiness: a population-based 5-year longitudinal study | 0.9 | 30 | Citations (PDF) |
| 164 | Increased blood pressure during the suggested immobilization test in Restless Legs Syndrome | 0.9 | 10 | Citations (PDF) |
| 165 | Genetic, Structural, and Functional Evidence Link <i>TMEM175</i> to Synucleinopathies | 6.6 | 97 | Citations (PDF) |
| 166 | Pitolisant for Daytime Sleepiness in Patients with Obstructive Sleep Apnea Who Refuse Continuous Positive Airway Pressure Treatment. A Randomized Trial | 8.9 | 262 | Citations (PDF) |
| 167 | Measures of functional outcomes, work productivity, and quality of life from a randomized, phase 3 study of solriamfetol in participants with narcolepsy | 1.7 | 191 | Citations (PDF) |
| 168 | 0693 Effects Of Solriamfetol On 24-hour Blood Pressure Patterns In Participants With Excessive Daytime Sleepiness Associated With Obstructive Sleep ApneaSleep, 2020, 43, A264-A264 | 0.9 | 2 | Citations (PDF) |
| 169 | 0950 Effects of Sodium Oxybate (SXB) on Body Mass Index (BMI) in Pediatric Patients With NarcolepsySleep, 2020, 43, A361-A361 | 0.9 | 1 | Citations (PDF) |
| 170 | Gut microbiota composition is associated with narcolepsy type 1 | 6.7 | 27 | Citations (PDF) |
| 171 | 0753 Cataplexy-Free Days in a Phase 3, Placebo-Controlled, Double-Blind, Randomized Withdrawal Study of JZP-258 in Adults With Narcolepsy With CataplexySleep, 2020, 43, A286-A286 | 0.9 | 1 | Citations (PDF) |
| 172 | 0752 JZP-258 Dose Titration and Transition from Sodium Oxybate in a Placebo-Controlled, Double-Blind, Randomized Withdrawal Study in Adult Participants With Narcolepsy With CataplexySleep, 2020, 43, A286-A286 | 0.9 | 1 | Citations (PDF) |
| 173 | Hepcidin and ferritin levels in restless legs syndrome: a case–control study | 3.4 | 29 | Citations (PDF) |
| 174 | 0740 Quality of Life in Phase 3, Placebo-Controlled, Double-Blind, Randomized Withdrawal Study of JZP-258 in Adults with Narcolepsy with CataplexySleep, 2020, 43, A281-A282 | 0.9 | 1 | Citations (PDF) |
| 175 | 0772 Effects Of Solriamfetol On 24-hour Blood Pressure Patterns In Participants With Excessive Daytime Sleepiness Associated With NarcolepsySleep, 2020, 43, A293-A293 | 0.9 | 1 | Citations (PDF) |
| 176 | Increased Blood Pressure Dipping in Restless Legs Syndrome With Rotigotine: A Randomized Trial | 4.6 | 12 | Citations (PDF) |
| 177 | Association of CSF orexin-A levels and nocturnal sleep stability in patients with hypersomnolence | 1.0 | 39 | Citations (PDF) |
| 178 | 0768 Time Course Of Improvement In Excessive Daytime Sleepiness And Cataplexy During Treatment With Pitolisant In Patients With NarcolepsySleep, 2020, 43, A291-A292 | 0.9 | 0 | Citations (PDF) |
| 179 | Narcolepsy with cataplexy: Does age at diagnosis change the clinical picture? | 5.0 | 27 | Citations (PDF) |
| 180 | Depression and suicidal thoughts in untreated and treated narcolepsy | 1.0 | 60 | Citations (PDF) |
| 181 | 0750 Nocturnal Sleep Stability and Cerebrospinal Fluid Orexin-A Levels: Sleep and Wake BoutsSleep, 2020, 43, A285-A285 | 0.9 | 1 | Citations (PDF) |
| 182 | Prise en charge du sommeil et de la vigilance en période épidémique COVID-19. Propositions conjointes de la SFRMS, la SPLF et la SFP. Version 1–03 05 2020. | 0.1 | 3 | Citations (PDF) |
| 183 | Disturbed nighttime sleep in children and adults with rhythmic movement disorder | 0.9 | 9 | Citations (PDF) |
| 184 | CSF and serum ferritin levels in narcolepsy type 1 comorbid with restless legs syndrome | 3.8 | 13 | Citations (PDF) |
| 185 | GBA
variants in REM sleep behavior disorder | 1.0 | 68 | Citations (PDF) |
| 186 | Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy with and without Cataplexy: Subgroup Analysis of Efficacy and Safety Data by Cataplexy Status in a Randomized Controlled Trial | 6.3 | 16 | Citations (PDF) |
| 187 | Effects of an individualized exercise training program on severity markers of obstructive sleep apnea syndrome: a randomised controlled trial | 1.7 | 26 | Citations (PDF) |
| 188 | Fine‐Mapping of
SNCA
in Rapid Eye Movement Sleep Behavior Disorder and Overt Synucleinopathies | 6.6 | 58 | Citations (PDF) |
| 189 | Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder | 6.6 | 125 | Citations (PDF) |
| 190 | Variants in the Niemann–Pick type C gene NPC1 are not associated with Parkinson's disease | 3.4 | 19 | Citations (PDF) |
| 191 | Diagnosis of central disorders of hypersomnolence: A reappraisal by European experts | 8.7 | 172 | Citations (PDF) |
| 192 | Analysis of common and rare
VPS13C
variants in late-onset Parkinson disease | 2.8 | 26 | Citations (PDF) |
| 193 | SMPD1 variants do not have a major role in rapid eye movement sleep behavior disorder | 3.4 | 4 | Citations (PDF) |
| 194 | Narcolepsy Severity Scale: a reliable tool assessing symptom severity and consequences | 0.9 | 49 | Citations (PDF) |
| 195 | Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder | 1.0 | 86 | Citations (PDF) |
| 196 | Approches pratiques pour le diagnostic des parasomnies du sommeil lent | 0.1 | 0 | Citations (PDF) |
| 197 | Les futurs médicaments des troubles du sommeil et de la vigilance | 0.1 | 2 | Citations (PDF) |
| 198 | Kleine‐Levin syndrome is associated with <i>LMOD3</i> variants | 3.8 | 17 | Citations (PDF) |
| 199 | Impaired glycinergic transmission in hyperekplexia: a model of parasomnia overlap disorder | 3.8 | 11 | Citations (PDF) |
| 200 | Long-term use of pitolisant to treat patients with narcolepsy: Harmony III Study | 0.9 | 230 | Citations (PDF) |
| 201 | Clinical autonomic dysfunction in narcolepsy type 1 | 0.9 | 38 | Citations (PDF) |
| 202 | Efficacy of THN102 (a combination of modafinil and flecainide) on vigilance and cognition during 40‐hour total sleep deprivation in healthy subjects: Glial connexins as a therapeutic target | 2.6 | 23 | Citations (PDF) |
| 203 | Narcolepsy — clinical spectrum, aetiopathophysiology, diagnosis and treatment | 28.6 | 565 | Citations (PDF) |
| 204 | Validation of Multiple Sleep Latency Test for the diagnosis of pediatric narcolepsy type 1 | 1.0 | 60 | Citations (PDF) |
| 205 | Recent advances in treatment for narcolepsy | 3.5 | 88 | Citations (PDF) |
| 206 | Blood pressure profile and endothelial function in restless legs syndrome | 3.4 | 30 | Citations (PDF) |
| 207 | Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases | 2.6 | 112 | Citations (PDF) |
| 208 | Absence of Relationship Between Self-Reported Sleep Measures and Amyloid Load in Elderly Subjects | 2.4 | 21 | Citations (PDF) |
| 209 | A randomized study of solriamfetol for excessive sleepiness in narcolepsy | 6.6 | 308 | Citations (PDF) |
| 210 | Multiple treatment comparison in narcolepsy: a network meta-analysis—methodological concerns | 0.9 | 1 | Citations (PDF) |
| 211 | Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma | 2.6 | 92 | Citations (PDF) |
| 212 | Measurement of symptoms in idiopathic hypersomnia | 1.0 | 79 | Citations (PDF) |
| 213 | Shared T cell receptor chains in blood memory CD4+ T cells of narcolepsy type 1 patients | 6.6 | 10 | Citations (PDF) |
| 214 | <i>SMPD1</i> mutations, activity, and α‐synuclein accumulation in Parkinson's disease | 4.6 | 109 | Citations (PDF) |
| 215 | Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre studyBrain, 2019, 142, 744-759 | 8.4 | 995 | Citations (PDF) |
| 216 | Restless legs syndrome and iron deficiency in adults with attention-deficit/hyperactivity disorder | 0.9 | 32 | Citations (PDF) |
| 217 | Disorders of Arousal in adults: new diagnostic tools for clinical practice | 1.5 | 27 | Citations (PDF) |
| 218 | Knowledge Gaps in the Perioperative Management of Adults With Narcolepsy | 1.8 | 4 | Citations (PDF) |
| 219 | Dual orexin receptor antagonist induces changes in core body temperature in rats after exercise | 3.4 | 16 | Citations (PDF) |
| 220 | French Language Online Cognitive Behavioral Therapy for Insomnia Disorder: A Randomized Controlled Trial | 2.4 | 15 | Citations (PDF) |
| 221 | Common and rare GCH1 variants are associated with Parkinson's disease | 3.4 | 27 | Citations (PDF) |
| 222 | Impaired histaminergic neurotransmission in children with narcolepsy type 1 | 5.0 | 25 | Citations (PDF) |
| 223 | Histamine: neural circuits and new medications | 0.9 | 118 | Citations (PDF) |
| 224 | Validation of the French Version of the Weiss Functional Impairment Rating Scale–Self-Report in a Large Cohort of Adult Patients With ADHD | 2.8 | 17 | Citations (PDF) |
| 225 | Exploration of cardiac sympathetic adrenergic nerve activity in narcolepsy | 1.3 | 14 | Citations (PDF) |
| 226 | Reduced brain amyloid burden in elderly patients with narcolepsy type 1 | 6.6 | 31 | Citations (PDF) |
| 227 | Maintenance of Wakefulness Test, real and simulated driving in patients with narcolepsy/hypersomnia | 1.7 | 31 | Citations (PDF) |
| 228 | Predicting daytime sleepiness and fatigue: a 9-year prospective study in myotonic dystrophy type 1 | 3.4 | 32 | Citations (PDF) |
| 229 | Persistence of deep-tendon reflexes during partial cataplexy | 1.7 | 12 | Citations (PDF) |
| 230 | Cortico-Amygdala-Striatal Activation by Modafinil/Flecainide Combination | 2.7 | 18 | Citations (PDF) |
| 231 | Kinesthetic stimulation for obstructive sleep apnea syndrome: An “on-off” proof of concept trial | 3.4 | 5 | Citations (PDF) |
| 232 | Effect of psychostimulants on blood pressure profile and endothelial function in narcolepsy | 1.0 | 53 | Citations (PDF) |
| 233 | Association between serum hepcidin level and restless legs syndrome | 4.6 | 30 | Citations (PDF) |
| 234 | The distinguishing motor features of cataplexy: a study from video-recorded attacks | 0.9 | 38 | Citations (PDF) |
| 235 | Diagnostic criteria for disorders of arousal: A video‐polysomnographic assessment | 6.6 | 85 | Citations (PDF) |
| 236 | Complex HLA association in paraneoplastic cerebellar ataxia with anti-Yo antibodies | 2.3 | 29 | Citations (PDF) |
| 237 | Association study of essential tremor genetic loci in Parkinson's disease | 3.4 | 10 | Citations (PDF) |
| 238 | A provisional tool for the measurement of sleep satisfaction | 2.8 | 27 | Citations (PDF) |
| 239 | Alternative diagnostic criteria for idiopathic hypersomnia: A 32‐hour protocol | 6.6 | 90 | Citations (PDF) |
| 240 | LRRK2 protective haplotype and full sequencing study in REM sleep behavior disorder | 2.6 | 29 | Citations (PDF) |
| 241 | The clinical spectrum of childhood narcolepsy | 8.7 | 103 | Citations (PDF) |
| 242 | Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (<scp>MACVIA</scp>‐<scp>ARIA</scp>) ‐ <scp>EIP</scp> on <scp>AHA</scp> Twinning Reference Site (<scp>GARD</scp> research demonstration project) | 6.8 | 62 | Citations (PDF) |
| 243 | Incidence of narcolepsy after H1N1 influenza and vaccinations: Systematic review and meta-analysis | 8.7 | 187 | Citations (PDF) |
| 244 | Neural network analysis of sleep stages enables efficient diagnosis of narcolepsy | 13.7 | 327 | Citations (PDF) |
| 245 | POLLAR: Impact of air POLLution on Asthma and Rhinitis; a European Institute of Innovation and Technology Health (EIT Health) project | 2.6 | 78 | Citations (PDF) |
| 246 | REM sleep behaviour disorder | 47.2 | 421 | Citations (PDF) |
| 247 | Treatment of paediatric narcolepsy with sodium oxybate: a double-blind, placebo-controlled, randomised-withdrawal multicentre study and open-label investigation | 7.4 | 92 | Citations (PDF) |
| 248 | NREM sleep parasomnias as disorders of sleep-state dissociation | 28.6 | 173 | Citations (PDF) |
| 249 | Sequencing of the GBA coactivator, Saposin C, in Parkinson disease | 3.4 | 20 | Citations (PDF) |
| 250 | French consensus: Augmentation syndrome in restless legs syndrome | 0.7 | 10 | Citations (PDF) |
| 251 | Circulating follicular helper T cells exhibit reduced ICOS expression and impaired function in narcolepsy type 1 patients | 6.6 | 10 | Citations (PDF) |
| 252 | Exploring the clinical features of narcolepsy type 1 versus narcolepsy type 2 from European Narcolepsy Network database with machine learning | 3.4 | 48 | Citations (PDF) |
| 253 | Cardiac Sympathetic Activity differentiates Idiopathic and Symptomatic Rapid Eye Movement Sleep Behaviour Disorder | 3.4 | 26 | Citations (PDF) |
| 254 | Circadian Rhythm Disturbances in the Blind | 4.4 | 39 | Citations (PDF) |
| 255 | National Sleep Foundation's sleep quality recommendations: first report | 2.8 | 1,099 | Citations (PDF) |
| 256 | Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial | 17.9 | 328 | Citations (PDF) |
| 257 | Cerebrospinal fluid levels of orexin-A and histamine, and sleep profile within the Alzheimer process | 3.4 | 94 | Citations (PDF) |
| 258 | Hypersomnolence, Hypersomnia, and Mood Disorders | 5.3 | 86 | Citations (PDF) |
| 259 | RIC3 variants are not associated with Parkinson's disease in French-Canadians and French | 3.4 | 5 | Citations (PDF) |
| 260 | Narcolepsy | 47.2 | 257 | Citations (PDF) |
| 261 | Measurement of narcolepsy symptoms | 1.0 | 99 | Citations (PDF) |
| 262 | Is the Muscle the Only Potential Target of Desipramine in Obstructive Sleep Apnea Syndrome? | 8.9 | 4 | Citations (PDF) |
| 263 | Effects of 1‐month withdrawal of ventilatory support in hypercapnic myotonic dystrophy type 1 | 4.0 | 27 | Citations (PDF) |
| 264 | Rare missense mutations in P2RY11 in narcolepsy with cataplexyBrain, 2017, 140, 1657-1668 | 8.4 | 33 | Citations (PDF) |
| 265 | MEIS1 variant as a determinant of autonomic imbalance in Restless Legs Syndrome | 3.4 | 27 | Citations (PDF) |
| 266 | Reply to “Rigor, reproducibility and in vitro CSF assays: The devil in the details” | 6.6 | 0 | Citations (PDF) |
| 267 | Depression and Hypersomnia | 4.3 | 65 | Citations (PDF) |
| 268 | Low cerebrospinal fluid hypocretin levels during sudden infant death syndrome (SIDS) risk period | 1.7 | 7 | Citations (PDF) |
| 269 | Heterozygous PINK1 p.G411S in rapid eye movement sleep behaviour disorderBrain, 2017, 140, e32-e32 | 8.4 | 7 | Citations (PDF) |
| 270 | Identification of novel risk loci for restless legs syndrome in genome-wide association studies in individuals of European ancestry: a meta-analysis | 17.9 | 237 | Citations (PDF) |
| 271 | Narcolepsy Type 1 as an Autoimmune Disorder: Evidence, and Implications for Pharmacological Treatment | 6.3 | 37 | Citations (PDF) |
| 272 | Consensus. Prise en charge thérapeutique des patients hypersomniaques : quelle stratégie ? | 0.1 | 1 | Citations (PDF) |
| 273 | Incidence, worsening and risk factors of daytime sleepiness in a population-based 5-year longitudinal study | 3.4 | 83 | Citations (PDF) |
| 274 | Is adult-onset attention deficit/hyperactivity disorder frequent in clinical practice? | 3.1 | 9 | Citations (PDF) |
| 275 | Effect of sodium oxybate, modafinil, and their combination on disrupted nighttime sleep in narcolepsy | 1.7 | 32 | Citations (PDF) |
| 276 | Prevalence of obstructive sleep apnoea in acute coronary syndrome: Routine screening in intensive coronary care units | 0.3 | 3 | Citations (PDF) |
| 277 | French consensus. Idiopathic hypersomnia: Investigations and follow-up | 0.7 | 15 | Citations (PDF) |
| 278 | French consensus. Type 1 and type 2 Narcolepsy: Investigations and follow-up | 0.7 | 11 | Citations (PDF) |
| 279 | Comorbidity between central disorders of hypersomnolence and immune-based disorders | 1.0 | 61 | Citations (PDF) |
| 280 | The dementia-associated APOE ε4 allele is not associated with rapid eye movement sleep behavior disorder | 3.4 | 31 | Citations (PDF) |
| 281 | Vitamin D deficiency in type 1 narcolepsy: a reappraisal | 1.7 | 15 | Citations (PDF) |
| 282 | French consensus. Hypersomnolence: Evaluation and diagnosis | 0.7 | 13 | Citations (PDF) |
| 283 | French consensus. Management of patients with hypersomnia: Which strategy? | 0.7 | 42 | Citations (PDF) |
| 284 | Effect of sodium oxybate on disrupted nighttime sleep in patients with narcolepsy | 3.8 | 58 | Citations (PDF) |
| 285 | Consensus. Hypersomnolence : évaluation et limites nosographiques | 0.1 | 1 | Citations (PDF) |
| 286 | Temporal Changes in the Cerebrospinal Fluid Level of Hypocretin-1 and Histamine in Narcolepsy | 0.9 | 39 | Citations (PDF) |
| 287 | Familial Aggregation of Insomnia | 0.9 | 13 | Citations (PDF) |
| 288 | Test–Retest Reliability of the Multiple Sleep Latency Test in Central Disorders of Hypersomnolence | 0.9 | 129 | Citations (PDF) |
| 289 | Excessive Sleepiness and Longer Nighttime in Bed Increase the Risk of Cognitive Decline in Frail Elderly Subjects: The MAPT-Sleep Study | 4.0 | 34 | Citations (PDF) |
| 290 | To Increase Our Knowledge on Sleep, Sleep Disorders, and Chronobiology in the Neuroscience Field during the Next Decade | 2.4 | 1 | Citations (PDF) |
| 291 | [18F]Fludeoxyglucose-Positron Emission Tomography Evidence for Cerebral Hypermetabolism in the Awake State in Narcolepsy and Idiopathic Hypersomnia | 2.4 | 35 | Citations (PDF) |
| 292 | Non-24-Hour Sleep–Wake Rhythm Disorder in the Totally Blind: Diagnosis and Management | 2.4 | 52 | Citations (PDF) |
| 293 | Restless legs syndrome and cardiovascular diseases: A case-control study | 2.3 | 32 | Citations (PDF) |
| 294 | 0026 GENETIC LOCI IN PERIODIC HYPERSOMNIA/KLEINE-LEVIN SYNDROME TYPE | 0.9 | 3 | Citations (PDF) |
| 295 | Narcolepsy and Other Central Hypersomnias | 1.1 | 27 | Citations (PDF) |
| 296 | Is Restless Legs Syndrome Involved in Ambulation Related to Sleepwalking? | 0.9 | 6 | Citations (PDF) |
| 297 | The European Narcolepsy Network (EU‐NN) database | 3.8 | 56 | Citations (PDF) |
| 298 | Absence of γ‐aminobutyric acid‐a receptor potentiation in central hypersomnolence disorders | 6.6 | 60 | Citations (PDF) |
| 299 | Excessive daytime sleepiness and antipathogen drug consumption in the elderly: a test of the immune theory of sleep | 3.4 | 4 | Citations (PDF) |
| 300 | From radioimmunoassay to mass spectrometry: a new method to quantify orexin-A (hypocretin-1) in cerebrospinal fluid | 3.4 | 44 | Citations (PDF) |
| 301 | The role of the melanoma gene MC1R in Parkinson disease and REM sleep behavior disorder | 3.4 | 13 | Citations (PDF) |
| 302 | Treatment Options for Narcolepsy | 6.3 | 100 | Citations (PDF) |
| 303 | Management of Narcolepsy | 1.7 | 50 | Citations (PDF) |
| 304 | Risk Factor Profile in Parkinson’s Disease Subtype with REM Sleep Behavior Disorder | 3.3 | 21 | Citations (PDF) |
| 305 | CD8 T cell-mediated killing of orexinergic neurons induces a narcolepsy-like phenotype in mice | 7.5 | 136 | Citations (PDF) |
| 306 | High-dimensional single-cell analysis reveals the immune signature of narcolepsy | 9.2 | 121 | Citations (PDF) |
| 307 | Absence of NMDA receptor antibodies in the rare association between Type 1 Narcolepsy and Psychosis | 3.4 | 15 | Citations (PDF) |
| 308 | Smoking, Alcohol, Drug Use, Abuse and Dependence in Narcolepsy and Idiopathic Hypersomnia: A Case-Control Study | 0.9 | 41 | Citations (PDF) |
| 309 | Narcolepsy-Associated HLA Class I Alleles Implicate Cell-Mediated Cytotoxicity | 0.9 | 78 | Citations (PDF) |
| 310 | Impact of Astroglial Connexins on Modafinil Pharmacological PropertiesSleep, 2016, 39, 1283-1292 | 0.9 | 56 | Citations (PDF) |
| 311 | Analysis of DNAJC13 mutations in French-Canadian/French cohort of Parkinson's disease | 3.4 | 42 | Citations (PDF) |
| 312 | Impact of sleep disturbances on kidney function decline in the elderly | 8.7 | 27 | Citations (PDF) |
| 313 | Rotigotine in Hemodialysis-Associated Restless Legs Syndrome: A Randomized Controlled Trial | 1.4 | 40 | Citations (PDF) |
| 314 | From state dissociation to status dissociatus | 8.7 | 66 | Citations (PDF) |
| 315 | Narcolepsie : Lien avec l’infection et la vaccination antigrippale H1N1 ? | 0.1 | 0 | Citations (PDF) |
| 316 | Comparing Treatment Effect Measurements in Narcolepsy: The Sustained Attention to Response Task, Epworth Sleepiness Scale and Maintenance of Wakefulness TestSleep, 2015, 38, 1051-1058 | 0.9 | 59 | Citations (PDF) |
| 317 | Pain in Sleepwalking: A Clinical EnigmaSleep, 2015, 38, 1693-1698 | 0.9 | 42 | Citations (PDF) |
| 318 | Attention-Deficit/Hyperactivity Disorder (ADHD) Symptoms in Pediatric Narcolepsy: A Cross-Sectional StudySleep, 2015, 38, 1285-1295 | 0.9 | 142 | Citations (PDF) |
| 319 | GBA mutations are associated with Rapid Eye Movement Sleep Behavior Disorder | 3.8 | 137 | Citations (PDF) |
| 320 | Ictal SPECT in patients with rapid eye movement sleep behaviour disorderBrain, 2015, 138, e390-e390 | 8.4 | 9 | Citations (PDF) |
| 321 | Preliminary results on CSF biomarkers for hypothalamic dysfunction in Kleine–Levin syndrome | 1.7 | 31 | Citations (PDF) |
| 322 | HLA-DPB1 and HLA Class I Confer Risk of and Protection from Narcolepsy | 6.5 | 142 | Citations (PDF) |
| 323 | Clinical and practical considerations in the pharmacologic management of narcolepsy | 1.7 | 129 | Citations (PDF) |
| 324 | Kleine–Levin syndrome in 120 patients: Differential diagnosis and long episodes | 6.6 | 78 | Citations (PDF) |
| 325 | Interactions of the histamine and hypocretin systems in CNS disorders | 28.6 | 91 | Citations (PDF) |
| 326 | A multidimensional approach of impulsivity in adult attention deficit hyperactivity disorder | 3.1 | 53 | Citations (PDF) |
| 327 | Sleep Complaints and Metabolic Syndrome in an Elderly Population: The Three-City Study | 1.7 | 39 | Citations (PDF) |
| 328 | Impact of cytokine in type 1 narcolepsy: Role of pandemic H1N1 vaccination ? | 6.6 | 49 | Citations (PDF) |
| 329 | Parkinson’s Disease Genetic Loci in Rapid Eye Movement Sleep Behavior Disorder | 2.4 | 49 | Citations (PDF) |
| 330 | Risk factors for neurodegeneration in idiopathic rapid eye movement sleep behavior disorder: A multicenter study | 6.6 | 280 | Citations (PDF) |
| 331 | Catechol-O-methyltransferase, dopamine, and sleep-wake regulation | 8.7 | 81 | Citations (PDF) |
| 332 | Car Crashes and Central Disorders of Hypersomnolence: A French Study | 2.3 | 78 | Citations (PDF) |
| 333 | Widespread Hypermetabolism in Symptomatic and Asymptomatic Episodes in Kleine-Levin Syndrome | 2.3 | 40 | Citations (PDF) |
| 334 | Daytime Sleepiness in Parkinson’s Disease: A Reappraisal | 2.3 | 67 | Citations (PDF) |
| 335 | Hypocretin and brain β-amyloid peptide interactions in cognitive disorders and narcolepsy | 4.0 | 51 | Citations (PDF) |
| 336 | La narcolepsie avec cataplexie : une maladie auto-immune ? | 0.2 | 5 | Citations (PDF) |
| 337 | Novel Approach Identifies SNPs in SLC2A10 and KCNK9 with Evidence for Parent-of-Origin Effect on Body Mass Index | 3.2 | 85 | Citations (PDF) |
| 338 | Challenges in Diagnosing Narcolepsy without Cataplexy: A Consensus StatementSleep, 2014, 37, 1035-1042 | 0.9 | 168 | Citations (PDF) |
| 339 | Lower wake resting sympathetic and cardiovascular activities in narcolepsy with cataplexy | 1.0 | 56 | Citations (PDF) |
| 340 | Quality of Life in Children with Narcolepsy | 5.0 | 71 | Citations (PDF) |
| 341 | Objective daytime sleepiness in patients with somnambulism or sleep terrors | 1.0 | 45 | Citations (PDF) |
| 342 | A comprehensive rehabilitation program improves disease severity in patients with obstructive sleep apnea syndrome: a pilot randomized controlled study | 1.7 | 66 | Citations (PDF) |
| 343 | Hypertension and sleep: Overview of a tight relationship | 8.7 | 220 | Citations (PDF) |
| 344 | Comorbidity and medication in REM sleep behavior disorder | 1.0 | 104 | Citations (PDF) |
| 345 | Consistent abnormalities in metabolic network activity in idiopathic rapid eye movement sleep behaviour disorderBrain, 2014, 137, 3122-3128 | 8.4 | 153 | Citations (PDF) |
| 346 | Autonomic symptoms in idiopathic REM behavior disorder: a multicentre case–control study | 3.4 | 103 | Citations (PDF) |
| 347 | Impulse control disorder and rapid eye movement sleep behavior disorder in Parkinson's disease | 2.6 | 22 | Citations (PDF) |
| 348 | From Phenomenology to Neurophysiological Understanding of Hallucinations in Children and Adolescents | 3.9 | 84 | Citations (PDF) |
| 349 | Depressive feelings in children with narcolepsy | 1.7 | 68 | Citations (PDF) |
| 350 | Cerebrospinal fluid and serum cytokine profiles in narcolepsy with cataplexy: A case-control study | 4.5 | 42 | Citations (PDF) |
| 351 | Cataplexy—clinical aspects, pathophysiology and management strategy | 28.6 | 176 | Citations (PDF) |
| 352 | Impact of acute administration of sodium oxybate on nocturnal sleep polysomnography and on multiple sleep latency test in narcolepsy with cataplexy | 1.7 | 35 | Citations (PDF) |
| 353 | DQB1 Locus Alone Explains Most of the Risk and Protection in Narcolepsy with Cataplexy in Europe | 0.9 | 187 | Citations (PDF) |
| 354 | Hypersomnia and depressive symptoms: methodological and clinical aspects | 7.1 | 126 | Citations (PDF) |
| 355 | Clinical, polysomnographic and genome‐wide association analyses of narcolepsy with cataplexy: a European Narcolepsy Network study | 3.8 | 208 | Citations (PDF) |
| 356 | Daytime Sleepiness and Myotonic Dystrophy | 4.4 | 75 | Citations (PDF) |
| 357 | Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy—a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group | 1.7 | 229 | Citations (PDF) |
| 358 | Rapid eye movement sleep behavior disorder and rapid eye movement sleep without atonia in narcolepsy | 1.7 | 110 | Citations (PDF) |
| 359 | Daytime somnolence in adult sleepwalkers | 1.7 | 31 | Citations (PDF) |
| 360 | Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial | 17.9 | 340 | Citations (PDF) |
| 361 | Hypnotics and mortality in an elderly general population: a 12-year prospective study | 7.1 | 71 | Citations (PDF) |
| 362 | Management of narcolepsy during pregnancy | 1.7 | 65 | Citations (PDF) |
| 363 | Decision making and addictive behaviors in narcolepsy with cataplexy | 1.0 | 2 | Citations (PDF) |
| 364 | Mazindol in narcolepsy and idiopathic and symptomatic hypersomnia refractory to stimulants: A long-term chart review | 1.7 | 82 | Citations (PDF) |
| 365 | Narcolepsy as an adverse event following immunization: Case definition and guidelines for data collection, analysis and presentation | 3.1 | 60 | Citations (PDF) |
| 366 | Impact of Obesity in Children with Narcolepsy | 5.0 | 81 | Citations (PDF) |
| 367 | Quel apport des centres de référence maladies rares dans la prise en charge des hypersomnies rares ? | 0.7 | 0 | Citations (PDF) |
| 368 | Narcolepsie avec cataplexie : maladie modèle de somnolence diurne | 0.0 | 0 | Citations (PDF) |
| 369 | Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder | 1.7 | 373 | Citations (PDF) |
| 370 | Restless legs syndrome outside the blood–brain barrier – Exacerbation by domperidone in Parkinson's disease | 2.6 | 27 | Citations (PDF) |
| 371 | Treatment options in narcolepsy | 1.0 | 0 | Citations (PDF) |
| 372 | Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in FranceBrain, 2013, 136, 2486-2496 | 8.4 | 214 | Citations (PDF) |
| 373 | Clinical and polysomnographic course of childhood narcolepsy with cataplexyBrain, 2013, 136, 3787-3795 | 8.4 | 126 | Citations (PDF) |
| 374 | ImmunoChip Study Implicates Antigen Presentation to T Cells in Narcolepsy | 3.2 | 226 | Citations (PDF) |
| 375 | Family history of idiopathic REM behavior disorder | 1.0 | 57 | Citations (PDF) |
| 376 | Restless legs syndrome | 2.5 | 103 | Citations (PDF) |
| 377 | Facial expression recognition and emotional regulation in narcolepsy with cataplexy | 3.8 | 12 | Citations (PDF) |
| 378 | Excessive sleep duration and quality of life | 6.6 | 149 | Citations (PDF) |
| 379 | Narcolepsy and pregnancy: a retrospective European evaluation of 249 pregnancies | 3.8 | 60 | Citations (PDF) |
| 380 | Functional Impairment in Adult Sleepwalkers: A Case-Control Study | 0.9 | 115 | Citations (PDF) |
| 381 | Effect of Psychostimulants on Impulsivity and Risk Taking in Narcolepsy with CataplexySleep, 2013, 36, 1335-1340 | 0.9 | 29 | Citations (PDF) |
| 382 | Decision-Making, Reward-Seeking Behaviors and Dopamine Agonist Therapy in Restless Legs SyndromeSleep, 2013, 36, 1501-1507 | 0.9 | 59 | Citations (PDF) |
| 383 | Reward-based behaviors and emotional processing in human with narcolepsy-cataplexy | 2.4 | 30 | Citations (PDF) |
| 384 | Disrupted Nighttime Sleep in Narcolepsy | 2.8 | 192 | Citations (PDF) |
| 385 | Insomnia, Daytime Sleepiness and Cardio-Cerebrovascular Diseases in the Elderly: A 6-Year Prospective Study | 2.3 | 53 | Citations (PDF) |
| 386 | Differences in Brain Morphological Findings between Narcolepsy with and without Cataplexy | 2.3 | 30 | Citations (PDF) |
| 387 | Prevalence and comorbidity of nocturnal wandering in the US adult general population | 1.0 | 114 | Citations (PDF) |
| 388 | Conflicts of Interest—Reply | 12.6 | 0 | Citations (PDF) |
| 389 | Operational Definitions and Algorithms for Excessive Sleepiness in the General Population | 12.6 | 119 | Citations (PDF) |
| 390 | Excessive Sleepiness is Predictive of Cognitive Decline in the ElderlySleep, 2012, 35, 1201-1207 | 0.9 | 205 | Citations (PDF) |
| 391 | Trajectories of Sleep Complaints From Early Midlife to Old Age: Longitudinal Modeling Study | 0.9 | 16 | Citations (PDF) |
| 392 | Rhythmic movement disorder associated with restless legs syndrome | 1.7 | 7 | Citations (PDF) |
| 393 | Age-related changes in sleep in inbred mice are genotype dependent | 3.4 | 84 | Citations (PDF) |
| 394 | Decreased fat oxidation during exercise in severe obstructive sleep apnoea syndrome | 3.5 | 2 | Citations (PDF) |
| 395 | Narcolepsy and effectiveness of gamma-hydroxybutyrate (GHB): A systematic review and meta-analysis of randomized controlled trials | 8.7 | 125 | Citations (PDF) |
| 396 | Myotonic dystrophy type 1, daytime sleepiness and REM sleep dysregulation | 8.7 | 78 | Citations (PDF) |
| 397 | The burden of narcolepsy with cataplexy: How disease history and clinical features influence socio-economic outcomes | 1.7 | 79 | Citations (PDF) |
| 398 | Executive Control of Attention in Narcolepsy | 2.3 | 71 | Citations (PDF) |
| 399 | Predictors of Hypocretin (Orexin) Deficiency in Narcolepsy Without CataplexySleep, 2012, 35, 1247-1255 | 0.9 | 201 | Citations (PDF) |
| 400 | Normal Cerebrospinal Fluid Histamine and tele-Methylhistamine Levels in Hypersomnia ConditionsSleep, 2012, 35, 1359-1366 | 0.9 | 94 | Citations (PDF) |
| 401 | Altered Sleep-Related Blood Pressure Profile in Hypocretin-Deficient Narcoleptic Patients | 0.9 | 4 | Citations (PDF) |
| 402 | Suggested immobilization test for diagnosis of restless legs syndrome in Parkinson's disease | 4.6 | 45 | Citations (PDF) |
| 403 | Excessive daytime sleepiness and vascular events: The Three City Study | 6.6 | 83 | Citations (PDF) |
| 404 | Periodic leg movements during sleep in narcoleptic patients with or without restless legs syndrome | 3.8 | 43 | Citations (PDF) |
| 405 | Non-Dipping Blood Pressure Profile in Narcolepsy with Cataplexy | 2.3 | 108 | Citations (PDF) |
| 406 | Ventilatory disorders and facial growth: Benefits of early genioplasty | 1.9 | 7 | Citations (PDF) |
| 407 | Insomnia Symptoms in Older Adults: Associated Factors and Gender Differences | 1.7 | 251 | Citations (PDF) |
| 408 | Troubles ventilatoires et croissance faciale : intérêt de la génioplastie précoce | 1.9 | 10 | Citations (PDF) |
| 409 | Recurrent hypersomnia: A review of 339 cases | 8.7 | 122 | Citations (PDF) |
| 410 | Insomnia in central neurologic diseases – Occurrence and management | 8.7 | 106 | Citations (PDF) |
| 411 | High pain frequency in narcolepsy with cataplexy | 1.7 | 41 | Citations (PDF) |
| 412 | Benefit and risk of modafinil in idiopathic hypersomnia vs. narcolepsy with cataplexy | 1.7 | 78 | Citations (PDF) |
| 413 | Melanin concentrating hormone in central hypersomnia | 1.7 | 25 | Citations (PDF) |
| 414 | Daytime Sleepiness and REM Sleep Characteristics in Myotonic Dystrophy: A Case-Control Study | 0.9 | 85 | Citations (PDF) |
| 415 | Comments on the Letter to the Editor by Ferri et al. on Autonomic Response to Periodic Leg Movements in Sleep in Narcolepsy-Cataplexy | 0.9 | 0 | Citations (PDF) |
| 416 | Comment on the Letter to the Editor By Dr. Marcus on the Association between Narcolepsy and H1N1 Exposure | 0.9 | 2 | Citations (PDF) |
| 417 | Autonomic Response to Periodic Leg Movements during Sleep in Narcolepsy-Cataplexy | 0.9 | 46 | Citations (PDF) |
| 418 | Decision Making in Narcolepsy with Cataplexy | 0.9 | 64 | Citations (PDF) |
| 419 | Low Vitamin D in Narcolepsy with Cataplexy | 2.3 | 33 | Citations (PDF) |
| 420 | Current and Future Therapeutic Approaches In Narcolepsy | 0.5 | 3 | Citations (PDF) |
| 421 | Insomnia and Daytime Sleepiness Are Risk Factors for Depressive Symptoms in the ElderlySleep, 2011, 34, 1103-1110 | 0.9 | 275 | Citations (PDF) |
| 422 | Histamine and tele-methylhistamine quantification in cerebrospinal fluid from narcoleptic subjects by liquid chromatography tandem mass spectrometry with precolumn derivatization | 2.4 | 41 | Citations (PDF) |
| 423 | The improvement of movement and speech during rapid eye movement sleep behaviour disorder in multiple system atrophyBrain, 2011, 134, 856-862 | 8.4 | 72 | Citations (PDF) |
| 424 | Complex movement disorders at disease onset in childhood narcolepsy with cataplexyBrain, 2011, 134, 3480-3492 | 8.4 | 175 | Citations (PDF) |
| 425 | Genome-Wide Association Study Identifies Novel Restless Legs Syndrome Susceptibility Loci on 2p14 and 16q12.1 | 3.2 | 176 | Citations (PDF) |
| 426 | Post-H1N1 Narcolepsy-CataplexySleep, 2010, 33, 1428-1430 | 0.9 | 191 | Citations (PDF) |
| 427 | Restless Legs Syndrome is Frequent in Narcolepsy with Cataplexy Patients | 0.9 | 71 | Citations (PDF) |
| 428 | Polysomnographic diagnosis of idiopathic REM sleep behavior disorder | 4.6 | 270 | Citations (PDF) |
| 429 | Decision making in restless legs syndrome | 4.6 | 27 | Citations (PDF) |
| 430 | Cerebrospinal fluid histamine levels are decreased in patients with narcolepsy and excessive daytime sleepiness of other origin | 3.8 | 58 | Citations (PDF) |
| 431 | Genome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsy | 25.2 | 176 | Citations (PDF) |
| 432 | Quelle évaluation préthérapeutique d’un patient avec SAHOS nouvellement diagnostiqué ? | 0.3 | 8 | Citations (PDF) |
| 433 | Comment prendre en charge la somnolence associée à la maladie de Parkinson ? | 0.7 | 1 | Citations (PDF) |
| 434 | Impact de la génioplastie en période péripubertaire sur la croissance mandibulaire | 1.9 | 0 | Citations (PDF) |
| 435 | Syndrome des jambes sans repos : une maladie génétique ? | 2.7 | 4 | Citations (PDF) |
| 436 | Olfactory dysfunction in narcolepsy with cataplexy | 1.7 | 24 | Citations (PDF) |
| 437 | A brain PET study in patients with narcolepsy-cataplexy | 6.3 | 63 | Citations (PDF) |
| 438 | Impact of genioplasty on mandibular growth during puberty | 1.9 | 16 | Citations (PDF) |
| 439 | Elevated Tribbles homolog 2–specific antibody levels in narcolepsy patients | 10.6 | 279 | Citations (PDF) |
| 440 | Increased Immune Complexes of Hypocretin Autoantibodies in Narcolepsy | 2.3 | 36 | Citations (PDF) |
| 441 | A polysomnographic study of daytime sleepiness in myotonic dystrophy type 1 | 6.3 | 90 | Citations (PDF) |
| 442 | Excessive Daytime Sleepiness Is an Independent Risk Indicator for Cardiovascular Mortality in Community-Dwelling Elderly | 6.0 | 166 | Citations (PDF) |
| 443 | Pressure Reduction During Exhalation in Sleep Apnea Patients Treated by Continuous Positive Airway PressureChest, 2009, 136, 490-497 | 1.0 | 40 | Citations (PDF) |
| 444 | Normalization of hypocretin-1 in narcolepsy after intravenous immunoglobulin treatment | 1.0 | 94 | Citations (PDF) |
| 445 | Psychological health in central hypersomnias: the French Harmony study | 6.3 | 183 | Citations (PDF) |
| 446 | Fatigue and daytime sleepiness in patients with myotonic dystrophy type 1: To lump or split? | 0.7 | 70 | Citations (PDF) |
| 447 | Hypocretinergic dysfunction in neuromyelitis optica with coma-like episodes | 0.4 | 3 | Citations (PDF) |
| 448 | Fibromyalgie : exemple d’interactions entre sommeil et douleur | 0.0 | 1 | Citations (PDF) |
| 449 | An inverse agonist of the histamine H3 receptor improves wakefulness in narcolepsy: Studies in orexin−/− mice and patients | 5.1 | 266 | Citations (PDF) |
| 450 | Autoantibody profiling on high-density protein microarrays for biomarker discovery in the cerebrospinal fluid | 1.4 | 11 | Citations (PDF) |
| 451 | Le syndrome de Kleine-Levin | 0.7 | 28 | Citations (PDF) |
| 452 | Narcolepsie avec cataplexie | 0.7 | 3 | Citations (PDF) |
| 453 | Narcolepsie avec cataplexie chez l’enfant : particularités cliniques et approches thérapeutiques | 0.7 | 10 | Citations (PDF) |
| 454 | Hypocretinergic dysfunction in neuromyelitis optica with coma-like episodes | 6.3 | 36 | Citations (PDF) |
| 455 | Hypocretin and Human African Trypanosomiasis | 0.9 | 27 | Citations (PDF) |
| 456 | Chiari malformation and sleep related breathing disorders | 6.3 | 130 | Citations (PDF) |
| 457 | REVERSAL OF SYMPTOMATIC TUMORAL NARCOLEPSY, WITH NORMALIZATION OF CSF HYPOCRETIN LEVEL | 1.0 | 20 | Citations (PDF) |
| 458 | REM Sleep Characteristics in Narcolepsy and REM Sleep Behavior Disorder | 0.9 | 196 | Citations (PDF) |
| 459 | Family History of Insomnia in a Population-Based SampleSleep, 2007, 30, 1739-1745 | 0.9 | 97 | Citations (PDF) |
| 460 | Restless legs syndrome in narcolepsy: A side effect of sodium oxybate? | 1.7 | 29 | Citations (PDF) |
| 461 | Age-at-onset in restless legs syndrome: A clinical and polysomnographic study | 1.7 | 86 | Citations (PDF) |
| 462 | Narcolepsy and familial advanced sleep-phase syndrome: molecular genetics of sleep disorders | 3.2 | 21 | Citations (PDF) |
| 463 | Narcolepsy with cataplexy | 62.3 | 695 | Citations (PDF) |
| 464 | Insomnia in patients with neurodegenerative conditions | 1.7 | 156 | Citations (PDF) |
| 465 | A nationwide survey of excessive daytime sleepiness in Parkinson's disease in France | 4.6 | 109 | Citations (PDF) |
| 466 | Periodic leg movements during sleep and wakefulness in narcolepsy | 3.8 | 109 | Citations (PDF) |
| 467 | Determinants of excessive daytime sleepiness in a French community‐dwelling elderly population | 3.8 | 72 | Citations (PDF) |
| 468 | Chronic Hypersomnia | 4.3 | 7 | Citations (PDF) |
| 469 | Kleine–Levin syndrome in a 14-year-old girl: CSF hypocretin-1 measurements | 1.7 | 33 | Citations (PDF) |
| 470 | EFNS guidelines on management of narcolepsy | 3.5 | 250 | Citations (PDF) |
| 471 | Differential diagnosis in hypersomnia | 4.4 | 49 | Citations (PDF) |
| 472 | Follow-up of four narcolepsy patients treated with intravenous immunoglobulins | 6.6 | 59 | Citations (PDF) |
| 473 | No effect on cognitive function from daily mobile phone use | 1.3 | 65 | Citations (PDF) |
| 474 | Aerobic and Functional Capacities in a Selected Active Population of European Octogenarians | 1.7 | 12 | Citations (PDF) |
| 475 | Genes for normal sleep and sleep disorders | 3.8 | 63 | Citations (PDF) |
| 476 | Family studies in insomnia | 2.1 | 114 | Citations (PDF) |
| 477 | Genetics of normal and pathological sleep in humans | 8.7 | 128 | Citations (PDF) |
| 478 | Effect of age on MSLT results in patients with narcolepsy–cataplexy | 1.0 | 138 | Citations (PDF) |
| 479 | Effect of cognitive behavioural therapy for insomnia on sleep architecture and sleep EEG power spectra in psychophysiological insomnia | 3.8 | 122 | Citations (PDF) |
| 480 | A narcolepsy susceptibility locus maps to a 5Mb region of chromosome 21q | 6.6 | 56 | Citations (PDF) |
| 481 | Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset | 6.6 | 160 | Citations (PDF) |
| 482 | Aspects du sommeil normal | 0.1 | 6 | Citations (PDF) |
| 483 | La narcolepsie, de Westphal à l’hypocrétine | 2.7 | 0 | Citations (PDF) |
| 484 | Narcolepsie | 0.5 | 0 | Citations (PDF) |
| 485 | Somnolence et psychiatrie | 0.5 | 0 | Citations (PDF) |
| 486 | HLA and genetic susceptibility to sleepwalking | 7.8 | 192 | Citations (PDF) |
| 487 | Clinical aspects and pathophysiology of narcolepsy | 1.3 | 129 | Citations (PDF) |
| 488 | Energy cost of walking and gait instability in healthy 65- and 80-yr-olds | 2.8 | 207 | Citations (PDF) |
| 489 | CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions | 6.3 | 292 | Citations (PDF) |
| 490 | Pharmacogenomics in the treatment of narcolepsy | 1.5 | 22 | Citations (PDF) |
| 491 | Month of Birth as a Risk Factor for Narcolepsy | 0.9 | 64 | Citations (PDF) |
| 492 | Aerobic determinants of the decline in preferred walking speed in healthy, active 65- and 80-year-olds | 2.3 | 56 | Citations (PDF) |
| 493 | Kleine-Levin syndrome | 1.0 | 239 | Citations (PDF) |
| 494 | Arousal Reactions in Sleepwalking and Night Terrors in Adults: The Role of Respiratory Events | 0.9 | 104 | Citations (PDF) |
| 495 | Severity of Narcolepsy Among French of Different Ethnic Origins (South of France and Martinique) | 0.9 | 22 | Citations (PDF) |
| 496 | Idiopathic Hypersomnia | 8.7 | 179 | Citations (PDF) |
| 497 | Le sommeil du fibromyalgique : revue des données cliniques et polygraphiques | 2.2 | 43 | Citations (PDF) |
| 498 | MAO-A and COMT polymorphisms and gene effects in narcolepsy | 7.8 | 115 | Citations (PDF) |
| 499 | Age at onset of narcolepsy in two large populations of patients in France and Quebec | 1.0 | 407 | Citations (PDF) |
| 500 | 10.1016/s0246-1072(19)30119-1 | 0.0 | 0 | Citations (PDF) |
| 501 | Loss of the transcription factor Meis1 prevents sympathetic neurons target-field innervation and increases susceptibility to sudden cardiac death | 1.6 | 38 | Citations (PDF) |
| 502 | Actigraphy against 32‐hour polysomnography in patients with suspected idiopathic hypersomnia | 3.8 | 5 | Citations (PDF) |
| 503 | Sleep During Pandemic Times: Summary of Findings and Future Outlook Through the Lens of the International
COVID
Sleep Study (
ICOSS
) | 3.8 | 1 | Citations (PDF) |
| 504 | Sleep overestimation differentiates between participants with suspected idiopathic hypersomnia | 0.9 | 4 | Citations (PDF) |
| 505 | Present and Future of Central Disorders of Hypersomnolence | 3.8 | 2 | Citations (PDF) |
| 506 | Characteristics of maintenance of wakefulness test in drug-naïve patients with narcolepsy type 1 and type 2, and relationship with other measures of sleepiness | 0.9 | 1 | Citations (PDF) |
| 507 | Depressive symptoms and suicidal thoughts in idiopathic hypersomnia: a cross-sectional and longitudinal study | 0.9 | 0 | Citations (PDF) |
| 508 | Management of Insomnia Complaints by Non‐Sleep Specialist Physicians: A French <scp>DELPHI</scp> Consensus | 3.8 | 0 | Citations (PDF) |
| 509 | 16-mer hypocretin-1/orexin-A in cerebrospinal fluid to diagnose narcolepsy | 0.9 | 2 | Citations (PDF) |
| 510 | Age at Onset and Delays in Diagnosis of Central Disorders of Hypersomnolence Over the Past 30 Years | 3.8 | 0 | Citations (PDF) |
| 511 | Lucid Dreaming: Not Just Awareness, but Agency | 3.8 | 0 | Citations (PDF) |
| 512 | Once‐Nightly Sodium Oxybate Meets American Academy of Sleep Medicine Criteria for Treatment of Narcolepsy | 3.8 | 1 | Citations (PDF) |
| 513 | Effects of High- Versus Low-Sodium Oxybate on Blood Pressure in Patients With Narcolepsy | 6.6 | 0 | Citations (PDF) |
| 514 | A new decision-making approach for residual excessive daytime sleepiness in individuals treated for obstructive sleep apnea–hypopnea syndrome: the blob-algorithm proposition | 0.9 | 0 | Citations (PDF) |
| 515 | Lack of epistatic interaction of
<i>SNCA</i>
with
<i>APOE</i>
in synucleinopathies | 3.6 | 0 | Citations (PDF) |
| 516 | Sleep time and SOREMPs features support idiopathic hypersomnia and narcolepsy type 2 as a single disease entity | 0.9 | 0 | Citations (PDF) |
| 517 | Classification and clustering on nocturnal polysomnography: distinctions and overlaps between central disorders of hypersomnolence | 0.9 | 1 | Citations (PDF) |
| 518 | Effects of low-sodium oxybate on diary-based sleep time in a clinical study in adults with idiopathic hypersomnia | 1.7 | 0 | Citations (PDF) |
| 519 | Lack of association between G6PD variants and Parkinson disease | 1.6 | 0 | Citations (PDF) |
| 520 | Idiopathic hypersomnia is a 24-hour disorder | 2.8 | 0 | Citations (PDF) |
| 521 | Perspectives on idiopathic hypersomnia: diagnostic challenges, unknown pathophysiological, and emerging therapeutic strategies | 0.9 | 0 | Citations (PDF) |
